Skip to Content
  • A Look at Antibody Therapies

    Since we were just talking about antibody therapies in immuno-oncology, here’s a timely column by Bruce Booth at LifeSciVC on antibody therapies in genera… Read More
  • Bill Ackman, Pompey, and You

    It’s been about a year since Valeant Pharmaceuticals fell apart into a pile of smoldering rubble. As that link details, its biggest investor and biggest f… Read More
  • The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarro… Read More
  • Out of Ideas?

    The Wall Street Journal came out with a series of articles on innovation in the US, and the biopharma industry features quite a bit in them. The lead one is an… Read More
  • Productivity Over the Years

    The last couple of years have been very good for the number of drug approvals, reversing a rather worrying trend. But are these data points themselves enough to… Read More
Page 1 of 3812345...102030...Last »